AGENHealthcare · BiotechnologyThe 2 Wall Street analysts covering Agenus, Inc. hold a median 12-month price target of $20 — +181.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Agenus, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Volatility (26): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AGEN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +181.0% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $30 → $25 |
| 30 July 2026 | B. Riley Securities | Maintains | Buy | $8.00 → $14 |
| 30 July 2026 | B. Riley Securities | Maintains | Buy | — |
| 13 July 2026 | HC Wainwright & Co. | Maintains | Buy | $23 → $30 |
| 13 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 June 2025 | Baird | Maintains | Neutral | — |
| 4 June 2025 | HC Wainwright & Co. | Upgrade | Buy | — |
| 13 May 2025 | Baird | Maintains | Neutral | — |
| 13 May 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 30 Apr 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 18 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 12 Mar 2025 | Baird | Maintains | Neutral | — |
| 12 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 22 Jan 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 5 Dec 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 29 Nov 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 12 Nov 2024 | HC Wainwright & Co. | Maintains | Neutral | — |
| 14 Aug 2024 | B. Riley Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AGEN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Agenus, Inc. returned +46.4% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 69% of US stocks
Cheaper than 48% of US stocks
Cheaper than 95% of US stocks
Cheaper than 45% of US stocks
Higher than 80% of US stocks
Higher than 68% of US stocks
Higher than 70% of US stocks
Higher than 88% of US stocks
Higher than 98% of US stocks
Higher than 44% of US stocks
Higher than 95% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Agenus, Inc. has a market value of $312.4M and an enterprise value of $327.6M.
Revenue in the twelve months to 30 June 2026: $132.7M. The latest quarter grew 34.4% year on year.
Net income over the same four quarters: $91.9M, a 69.3% net margin.
Free cash flow in the twelve months to 30 June 2026: −$98.5M.
Agenus, Inc. spent $54K on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 2.3×; forward P/E: −115.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Agenus, Inc. employs 81 people — $1.6M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Agenus, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The item is a transcript of a shareholder/analyst call for Agenus Inc. (AGEN), published by Seeking Alpha. No substantive details beyond the transcript's availability are provided in the excerpt.
Why it matters — A transcript of an Agenus shareholder/analyst call gives investors a record of management's commentary and answers to analyst questions.
Agenus announced that a poster on botensilimab combined with balstilimab has been accepted for presentation at the International Gynecologic Cancer Society Annual Global Meeting, October 1-3, 2026, in Montreal. The presentation will feature results from its recurrent ovarian cancer study.
Why it matters — The presentation is an opportunity for AGEN watchers to see three-year overall survival data on the BOT+BAL combination in recurrent ovarian cancer, a key readout for the company's pipeline.
Agenus announced that its Chief Commercial Officer and Head of Corporate Development and Investor Relations will participate in fireside chats and one-on-one investor meetings at the Cantor Global Healthcare Conference in September 2026.
Why it matters — The company's leadership will have scheduled opportunities to present and discuss Agenus with investors and analysts at a major healthcare conference.
Agenus announced a peer-reviewed publication of mature Phase 1b results from the fully enrolled C-800-01 cohort evaluating botensilimab plus balstilimab in 123 heavily pre-treated patients with microsatellite-stable metastatic colorectal cancer without active liver metastases. The publication links the regimen's durable survival to its distinct immune-priming mechanism.
Why it matters — A peer-reviewed publication of mature Phase 1b data highlights the clinical evidence base for Agenus's lead combination in a difficult-to-treat patient population.
Agenus announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST trial evaluating neoadjuvant botensilimab (BOT) and balstilimab (BAL) in patients with resectable colon cancer, reporting deep pathologic responses and no observed recurrences.
Why it matters — Agenus watchers would care because this peer-reviewed publication provides updated clinical data on its lead investigational immunotherapy combination in colon cancer.
The 2 Wall Street analysts covering Agenus, Inc. have a median 12-month price target of $20, with estimates ranging from $14 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Agenus, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Agenus, Inc. 91 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Agenus, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +181.0% from the last close, and Ticker Nerd's factor model ranks Agenus, Inc. 91 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Agenus, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $25 over the next 12 months.
Agenus, Inc. returned +46.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology and immune-based therapies for cancer.
The most recent item we track (Seeking Alpha, 11 Sept 2026): "Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript". The item is a transcript of a shareholder/analyst call for Agenus Inc. (AGEN), published by Seeking Alpha. No substantive details beyond the transcript's availability are provided in the excerpt.
Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology and immune-based therapies for cancer. Agenus develops a pipeline of checkpoint antibodies, immune modulators, and combination regimens designed to help the immune system recognize and attack tumors. Its current portfolio also includes vaccine adjuvants and cell therapy programs, supported by proprietary discovery platforms and in-house manufacturing and clinical development capabilities. The company’s lead programs center on botensilimab and balstilimab, which are being advanced in multiple solid-tumor settings, including colorectal cancer and other difficult-to-treat cancers. Agenus also works through subsidiaries and partners to support adoptive cell therapies and adjuvant technologies, giving it a broad role across the immunotherapy value chain. Founded in 1994 and headquartered in Lexington, Massachusetts, Agenus Inc. remains a specialist developer in the cancer immunotherapy market.
CEO Dr. Garo H. Armen Ph.D. · 81 employees · United States · https://www.agenusbio.com
